Future viral vectors for the delivery of asymptomatic herpes epitope-based immunotherapeutic vaccines

Future Virology

Volumn 5, Issue 5, 2010, Pages 525-528

  Chentoufi, Aziz Alami ^a   Benmohamed, Lbachir ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

animal models; asymptomatic; clinical trial; epitope; genital herpes; herpes simplex virus; immunotherapeutic; ocular herpes; symptomatic; vaccine; vectors

Indexed keywords

EPITOPE; HERPES VACCINE; HERPESVIRUS VECTOR;

EDITORIAL; GENE DELETION; GENE EXPRESSION; HERPES SIMPLEX; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRUS IMMUNITY; VIRUS REPLICATION;

ANIMALIA; HERPES; SIMPLEXVIRUS;

EID: 77957317515     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.44     Document Type: Editorial

References (17)

1. Smith GL, Mackett M, Moss B: Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen. Nature 302, 490-495 (1983).
2. Draper SJ, Heeney JL: Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Microbiol. 8, 62-73 (2010).
3. Barzon L, Zanusso M, Colombo F, Palu G: Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant gliomas. Cancer Gene Ther. 13, 539-554 (2006).
4. BenMohamed L, Wechsler SL, Nesburn AB: Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect. Dis. 2, 425-431 (2002).
5. La Rosa C, Wang Z, Lacey SF et al.: In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modifed vaccinia Ankara. Exp. Hematol. 34(4), 497-507 (2006).
6. Dudek T, Knipe DM: Replication-defective viruses as vaccines and vaccine vectors. Virology 344, 230-239 (2006).
7. Epstein AL, Marconi P, Argnani R, Manservigi R: HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy. Curr. Gene Ther. 5, 445-458 (2005).
8. Epstein AL: Progress and prospects: biological properties and technological advances of herpes simplex virus type 1-based amplicon vectors. Gene Ther. 16, 709-715 (2009).
9. Goins WF, Wolfe D, Krisky DM et al.: Delivery using herpes simplex virus: an overview. Methods Mol. Biol. 246, 257-299 (2004).
10. Furlan R, Bergami A, Brambilla e et al.: HSV-1-mediated IL-1 receptor antagonist gene therapy ameliorates MOG (35-55) - induced experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther. 14, 93-98 (2007).
11. Glorioso JC, Fink DJ: Herpes vectormediated gene transfer in the treatment of chronic pain. Mol. Ther. 17, 13-18 (2009).
12. Harrow S, Papanastassiou V, Harland J et al.: HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther. 11, 1648-1658 (2004).
13. Markert JM, Liechty PG, Wang W et al.: Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol. Ther. 17, 199-207 (2009).
14. Kaur A, Sanford HB, Garry D et al.: Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Virology 357, 199-214 (2007).
15. Hoshino Y, Pesnicak L, Dowdell KC et al.: Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J. Infect. Dis. 200, 1088-1095 (2009).
16. Parker JN, Pfister LA, Quenelle D et al.: Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine 24, 1644-1652 (2006).
17. Puntel M, Barrett RJ, Mondkar S et al.: Herpes simplex virus type 1 thymidine kinase sequence fused to the lacz gene increases levels of β-galactosidase activity per genome of high-capacity but not first-generation adenoviral vectors in vitro and in vivo. J. Virol. 83, 2004-2010 (2009).